National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Osimertinib (Tagrisso®) Adjuvant treatment stage IB-IIIA NSCLC. HTA ID: 21066

Osimertinib (Tagrisso®) is indicated for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

 

 

NCPE Assessment Process Complete
Rapid review commissioned 20/12/2021
Rapid review completed 13/01/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care.